{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:37:24Z","timestamp":1787236644954,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe malaria can be deadly and requires treatment with intravenous artesunate (IVAS). The Centers for Disease Control and Prevention provided IVAS starting 1 April 2019 for all patients with severe malaria in the United States. This study describes the safety and effectiveness of IVAS in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients meeting criteria for severe malaria April 2019\u2013December 2020 who received IVAS were included. Demographic, clinical, laboratory, adverse event, and outcome information were collected. Clinical presentation, time to reach 1% and 0% parasitemia, adverse events, and death were described using proportions, medians, interquartile range (IQR), and tests of significance for differences in proportions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 280 patients included, the majority were male (61.4%), Black (75.0%), with a median age of 35 years (IQR: 15.8\u201353.9). Most had Plasmodium falciparum (83.6%) with median parasitemia of 8.0% (IQR: 4.6\u201313.2). Of 170 patients with information, 159 (93.5%) reached\u2005\u22641% parasitemia by the third IVAS dose with a median time of 17.6 hours (IQR: 10.8\u201328.8), and 0% parasitemia in a median of 37.2 hours (IQR 27.2\u201355.2). Patients with parasite densities\u2005&amp;gt;10% and those requiring adjunct therapy had significantly higher parasite clearance times. Adverse events associated with IVAS were reported in 4.8% (n\u2005=\u200513 of 271). Eight patients had post-artesunate delayed hemolysis that resolved. There were 5 (1.8%) deaths, all attributable to severe malaria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IVAS is a safe and effective drug for the treatment of severe malaria in the United States; timely administration can be lifesaving.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciab570","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T15:13:53Z","timestamp":1624029233000},"page":"1965-1972","source":"Crossref","is-referenced-by-count":21,"title":["Safety and Effectiveness of Intravenous Artesunate for Treatment of Severe Malaria in the United States\u2014April 2019 Through December 2020"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2446-9199","authenticated-orcid":false,"given":"Francisca","family":"Abanyie","sequence":"first","affiliation":[{"name":"Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushama D","family":"Acharya","sequence":"additional","affiliation":[{"name":"Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Leavy","sequence":"additional","affiliation":[{"name":"Oberlin College, Department of Biology, Oberlin, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meara","family":"Bowe","sequence":"additional","affiliation":[{"name":"Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine R","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"2021121022511884700_CIT0001","doi-asserted-by":"crossref","DOI":"10.30875\/60123dd4-en","volume-title":"World malaria report 2020: 20 years of global progress and challenges","author":"World Health Organization.","year":"2020"},{"key":"2021121022511884700_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7002a1","article-title":"Malaria surveillance - United States, 2017","volume":"70","author":"Mace","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"2021121022511884700_CIT0003","first-page":"1","article-title":"Malaria surveillance - United States, 2007","volume":"58","author":"Mali","year":"2009","journal-title":"MMWR Surveill Summ"},{"key":"2021121022511884700_CIT0004","author":"National Travel and Tourism Office."},{"key":"2021121022511884700_CIT0005","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1345\/aph.1M732","article-title":"Intravenous artesunate for the treatment of severe malaria","volume":"44","author":"Hess","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2021121022511884700_CIT0006","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization.","year":"2015","edition":"3rd"},{"key":"2021121022511884700_CIT0007","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(05)67176-0","article-title":"Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial","volume":"366","author":"Dondorp","year":"2005","journal-title":"Lancet"},{"key":"2021121022511884700_CIT0008","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","article-title":"Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial","volume":"376","author":"Dondorp","year":"2010","journal-title":"Lancet"},{"key":"2021121022511884700_CIT0009","volume-title":"Guidelines for the treatment of malaria","author":"World Health Orgranization.","year":"2010","edition":"2nd"},{"key":"2021121022511884700_CIT0010","author":"Centers for Disease Control and Prevention."},{"key":"2021121022511884700_CIT0011","first-page":"753","article-title":"Update on cases of delayed hemolysis after parenteral artesunate therapy for malaria - United States, 2008 and 2013","volume":"63","author":"Paczkowski","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021121022511884700_CIT0012","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2875-11-102","article-title":"Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium","volume":"11","author":"Kreeftmeijer-Vegter","year":"2012","journal-title":"Malar J"},{"key":"2021121022511884700_CIT0013","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciz206","article-title":"Propensity score analysis of artesunate versus quinine for severe imported Plasmodium falciparum malaria in France","volume":"70","author":"El Ket","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021121022511884700_CIT0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12936-016-1673-z","article-title":"Severe malaria in Europe: an 8-year multi-centre observational study","volume":"16","author":"Kurth","year":"2017","journal-title":"Malar J"},{"key":"2021121022511884700_CIT0015","first-page":"1","article-title":"Malaria surveillance - United States, 2012","volume":"63","author":"Cullen","year":"2014","journal-title":"MMWR Surveill Summ"},{"key":"2021121022511884700_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6502a1","article-title":"Malaria Surveillance - United States, 2013","volume":"65","author":"Cullen","year":"2016","journal-title":"MMWR Surveill Summ"},{"key":"2021121022511884700_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6612a1","article-title":"Malaria surveillance - United States, 2014","volume":"66","author":"Mace","year":"2017","journal-title":"MMWR Surveill Summ"},{"key":"2021121022511884700_CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6805a1","article-title":"Malaria surveillance - United States, 2016","volume":"68","author":"Mace","year":"2019","journal-title":"MMWR Surveill Summ"},{"key":"2021121022511884700_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6707a1","article-title":"Malaria surveillance - United States, 2015","volume":"67","author":"Mace","year":"2018","journal-title":"MMWR Surveill Summ"},{"key":"2021121022511884700_CIT0020","author":"Centers for Disease Control and Prevention."},{"key":"2021121022511884700_CIT0021","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2014-02-555953","article-title":"Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins","volume":"124","author":"Jaur\u00e9guiberry","year":"2014","journal-title":"Blood"},{"key":"2021121022511884700_CIT0022","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/cid\/civ575","article-title":"Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: the TropNet Severe Malaria Study","volume":"61","author":"Kurth","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021121022511884700_CIT0023","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/INF.0000000000002417","article-title":"Intravenous artesunate for imported severe malaria in children treated in four tertiary care centers in Germany: a retrospective study","volume":"38","author":"B\u00e9lard","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2021121022511884700_CIT0024","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1475-2875-11-169","article-title":"Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia","volume":"11","author":"Rolling","year":"2012","journal-title":"Malar J"},{"key":"2021121022511884700_CIT0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2014.09.007","article-title":"Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence","volume":"29","author":"Rehman","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2021121022511884700_CIT0026","first-page":"5","article-title":"Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria\u2014worldwide, 2010\u20132012","volume":"62","author":"Briggs","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021121022511884700_CIT0027","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4269\/ajtmh.1996.54.62","article-title":"Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand","volume":"54","author":"Looareesuwan","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"2021121022511884700_CIT0028","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4269\/ajtmh.2001.64.247","article-title":"A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand","volume":"64","author":"Lef\u00e8vre","year":"2001","journal-title":"Am J Trop Med Hyg"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab570\/40811357\/ciab570.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/1965\/41608433\/ciab570.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/1965\/41608433\/ciab570.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T17:54:20Z","timestamp":1639158860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/1965\/6329244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,27]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab570","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,7,27]]}}}